00:01 , Aug 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
18:07 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a chemokine-targeting single-chain variable fragment (scFv)-based fusion protein that could help treat arthritis. Screening of a scFv library for binding to various human and mouse chemokines, engineering...
01:26 , Nov 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
19:02 , May 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
21:01 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia Mouse studies suggest inhibiting signaling between CCL3 and its receptors, CCR1 and CCR5 , could help treat juvenile myelomonocytic leukemia (JMML) in Noonan syndrome patients harboring activating SHP-2 mutations. In a mouse model...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

VBI Vaccines preclinical data

In an ex vivo model of CMV-positive GBM, VBI-1901 recruited and activated dendritic cells as measured by induction of interleukin-8 (IL-8; CXCL8 ) and macrophage inflammatory protein-1 alpha ( CCL3 ; MIP1A ). The product...
01:33 , Apr 19, 2016 |  BC Extra  |  Clinical News

Predictive biomarkers linked to cytokine release syndrome

Researchers led by David Teachey at the Children's Hospital of Pennsylvania and University of Pennsylvania think they have identified the first predictive biomarkers of severe cytokine release syndrome (CRS) in patients undergoing chimeric antigen receptor...
01:33 , Mar 13, 2015 |  BC Extra  |  Company News

Newco Annias debuts with glioblastoma vaccine

Immuno-oncology newco Annias Immunotherapeutics Inc. (Chapel Hill, N.C.) debuted with IP licensed from Duke University to a clinical-stage vaccine that targets solid tumors and a method to boost the vaccine's activity. CEO Reiner Laus told...